ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Feb 14, 2017
Is AbbVie a Value Trap?
Image Source: Express Scripts. With uncertainty surrounding the patent of blockbuster drug Humira, AbbVie is looking to deliver another success story from its pipeline. Is it headed for a patent cliff? Let’s take a look.
Jan 23, 2017
Have Bristol-Myers Squibb’s Shares Finally Found Support?
Image Source: kennijima. Bristol-Myers Squibb has seen its shares fall to $50 from nearly $80 in just the past few months as clinical outcomes of its crucial product Opdivo have come under fire. Have shares finally found support? Let’s have a look.
Jan 19, 2017
The Dreaded Patent Cliff: 3 Pharmaceutical Companies at Risk
Image Source: Global Panorama. Let's have a look at 3 pharmaceutical giants that may encounter some troubles in coming years.
Jan 6, 2017
CVS Health In The Bargain Bin? We Think So
Image Source: Mike Mozart. We are adding CVS Health to the newsletter portfolios.
Oct 31, 2016
Dividend Increases/Decreases for the Week Ending October 28
Let's take a look at companies raising/lowering their dividends this week.
Sep 24, 2016
Update on Teva and the Generics Market
Image Source: Teva. Best Ideas Newsletter portfolio holding has completed a major acquisition, further strengthening its position in the global generics market, and it expects the generics market to continue expanding at a solid rate.
Aug 10, 2016
Oncology News a Key Driver of Big Pharma
Image Source: Images Money. Oncology product portfolios and pipelines have been key factors in the big pharma industry as of late.
May 17, 2016
Big Pharma 1Q Earnings Roundup, Part II
Image Source: Paw Paw. Let’s take a look at the first quarter performance and some major news for some of the biggest players in the pharmaceuticals sector. Included in this article: ABBV, AGN, BMY, AMGN, MRK, PFE.
May 2, 2016
Gilead: What's Your Long Term Thesis?
Image Source: Gilead. We’re starting to see some even bigger risks at Gilead – long-term ones.
May 2, 2016
April Deals May Flower Future Growth
Image Source: Iqbal Osman. A series of mergers and acquisitions were announced in late April. Will the wave of deal making provide too big a shock to acquirers, or will their future growth trajectories flower? Let’s take a quick look at some of the deals and their impact on the companies involved.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.